HSD17B13
Description
The HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) is a protein-coding gene located on chromosome 4.
17Ξ²-Hydroxysteroid dehydrogenase type 13 (also known as 17Ξ²-HSD type 13) is an enzyme that in humans is encoded by the HSD17B13 gene. It is significantly up-regulated in the liver of patients with non-alcoholic fatty liver disease (NAFLD) and enhances lipogenesis.
In 2023, the first potent and selective HSD17B13 inhibitor, BI-3231, was reported. The inhibitor meets the quality criteria of a 'Donated Chemical Probe' as defined by the Structural Genomics Consortium.
HSD17B13 is also known as FLDP, HMFN0376, NIIL497, SCDR9, SDR16C3.
